Both of these gene-editing stocks are appealing, but which one reigns supreme?
News & Analysis: Editas Medicine
More pipeline activity than ever before could usher in a big boom for CRISPR gene-editing stocks next year.
An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
The good, the bad, and the ugly behind this gene-editing stock.
An amended collaboration agreement limited the types of immune cells that will be pursued by the duo, but that could create more value for Editas Medicine in the long run.
The gene editing pioneer got a boost from a collaborator and a competitor.
These gene-editing trailblazers continue advancing exciting new approaches to treating inherited diseases.
A combination of several factors could be behind the biotech's big gain.
Here's why 2020's going to be a big year for three gene-editing stocks.
The industry's most advanced drug candidate based on CRISPR gene editing has data from the first two patients.